Subcutaneously administered interferon-gamma for the treatment of multidrug-resistant pulmonary tuberculosis  by Park, Seung-Kyu et al.
S
t
t
S
S
I
f
1
dubcutaneously administered interferon-gamma for
he treatment of multidrug-resistant pulmonary
uberculosis
eung-Kyu Park a, Sungae Cho b, In-Hee Lee a, Doo-Soo Jeon a,
ung-Hee Hong b, Raymond A. Smego Jr.c,*, Sang-Nae Cho b
nternational Journal of Infectious Diseases (2007) 11, 434—440
http://intl.elsevierhealth.com/journals/ijidaDepartment of Chest Surgery and the Clinical Research Center, National Masan Tuberculosis Hospital, Masan, South Korea
bDepartment of Microbiology, Yonsei University College of Medicine, Seoul, South Korea
cTuberculosis Research Section, NIAID-National Institutes of Health, Rockville, MD, USA
Received 12 April 2006; received in revised form 27 November 2006; accepted 4 December 2006
Corresponding Editor: Andy I.M. Hoepelman, Utrecht, The NetherlandsKEYWORDS
Tuberculosis;
Multidrug-resistant TB;
Interferon-gamma;
Subcutaneous injection
Summary
Objective: We evaluated the clinical and laboratory effects of subcutaneously administered
interferon-gamma (IFN-g) in the treatment of chronic and advanced multidrug-resistant tuber-
culosis (MDR-TB).
Design: Eight patients with sputum smear and culture persistently positive MDR-TB were sub-
cutaneously administered 2 million international units of recombinant human IFN-g three times a
week for 24 weeks (72 doses total) between December 2002 and May 2003. Subjects also received
a customized drug regimen containing second- and third-line antituberculosis agents based upon
drug susceptibility testing and previous treatment history.
Results: Body weight remained stable or slightly decreased in all subjects during the study
period, and none displayed radiographic improvement on serial chest computed tomography
scanning. Sputum smears and cultures remained positive for all patients, and there was no
increase in the mean time to yield a positive culture (from 16.5  6.4 to 11.8  4.9 days). There
was no enhancement of cell-mediated immune responses in terms of production of IFN-g or IL-10,
or of composition of lymphocytes among peripheral blood mononuclear cells. In four patients,
therapy was discontinued because of adverse reactions.
Conclusion: In patients with chronic and advanced MDR-TB, subcutaneous IFN-g treatment did
not result in improvement in clinical, radiologic, microbiologic, or immunologic parameters.
# 2007 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.* Corresponding author. Address: Oman Medical College, PO Box 391, PC 321, Al-Tareef, Sohar, Sultanate of Oman. Tel.: +968 268 44004x101;
ax: +968 268 43545.
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Over thepastdecadeabetterunderstandingof thehumanhost
immune response to tuberculosis has begun toemerge.Critical
components of this immune response are cytokines and med-
iators of cellular immunity, including T-lymphocytes and
macrophages. Mycobacterial antigens induce production of
inflammatory cytokines such as tumor necrosis factor-alpha
(TNF-a) and interleukin (IL)-1b, which serve to recruit more
lymphocytes that are generally of the T-helper phenotype.
These cells produce substances such as the macrophage-acti-
vating lymphokine and interferon-gamma (IFN-g). The macro-
phages activated by IFN-g are stimulated to enhance
intracellular killing ofmycobacteria.1—5 Individualswithmuta-
tions in thepathwayscontrolling theproductionof, or response
to, IFN-g and its inducer, IL-12, are more susceptible to myco-
bacterial infections than those without these mutations.6
At the time of diagnosis, the production of Mycobacterium
tuberculosis or mycobacterial antigen-induced IFN-g by per-
ipheral bloodmononuclear cells (PBMCs), mainly derived from
CD4+ lymphocytes, is depressed in most patients with active
tuberculosis compared to healthy control subjects.7 IFN-g
levels subsequently increase significantly during and following
successful antituberculosis therapy.2 Sputum and bronchoal-
veolar lavage (BAL) concentrations of IFN-g can reflect disease
activity.8,9 However, current data from experimental models
and studies of patients with pulmonary tuberculosis suggest
that whole blood production of IFN-g is the best correlate of
protective immunity against M. tuberculosis.10
Several reviews have suggested that immunotherapieswith
type I (Th1)-related cytokines such as IFN-g and interleukin-12
(IL-12) appear tobepromisingnewmodalities in the treatment
of resistantor refractory tuberculosis.6,11—13Anumberof small
pilot studies using aerosolized IFN-g or IFN-a for patients with
resistant pulmonary tuberculosis have reported beneficial,
although somewhat conflicting results.14—18 However, sys-
temic interferon such as that used as therapy for chronic
hepatitis B and C infection has been rarely used in the treat-
ment of tuberculosis.19,20 We describe herein our experience
with subcutaneously administered recombinant IFN-g in eight
patients with multidrug-resistant pulmonary tuberculosis
(MDR-TB). We also sought to determine the kinetics of T-cell
proliferative responses, Th1 (IFN-g) and Th2 (IL-10) cytokine
production, and lymphocyte composition, as well as highlight
the tolerability and efficacy of this treatment modality.
Materials and methods
Study subjects
Eight study subjects with chronic, advanced MDR-TB were
enrolled from the inpatient service at our national TB referral
hospital inMasan, Korea. All subjects received antituberculous
drug therapy combined with subcutaneously administered
recombinant human IFN-g (LG Life Sciences, Inc., Daejeon,
Korea), 2 million IU three times weekly for 24 weeks (72 total
doses), between December 4, 2002 andMay 21, 2003. For each
subject, major outcome variables analyzed included treat-
ment sideeffects andeffects of IFN-gonclinical, radiographic,
microbiologic, and immunologic parameters. Concomitant use
of antituberculosis drug therapy was customized for each
subject based upon drug susceptibility testing and previoustreatment history, and consisted of conventional second-line
agents (e.g., prothionamide, cycloserine, para-amino salicylic
acid, streptomycin or kanamycin) plus clarithromycin, amox-
icillin—clavulanate, levofloxacin, and/or moxifloxacin. No
subsequent changes to the drug regimens were made during
the study period. In instances where second-line drug avail-
ability was limited, and if isoniazid and rifampin had been
previously prescribed for only a short duration, these two
latter agents were empirically included despite drug suscept-
ibility results. Antituberculous drugswere regularly self-admi-
nistered while IFN-g was administered by a study nurse.
Sputum samples for an acid-fast bacilli (AFB) smear and
culture, and blood samples for complete blood count, serum
electrolyte determinations, and liver enzyme testing were
obtained at the initial visit and bi-weekly throughout the 24-
week study. Peripheral blood mononuclear cell (PBMC) com-
position and cell-mediated immune responses were deter-
mined at baseline and at various intervals during the study
period. Monitoring included T-lymphocyte proliferation test-
ing, IFN-g responses via enzyme-linked immunosorbent assay
(ELISA), and fluorescence-activated cell sorting (FACS) stain-
ing analysis of circulating PBMCs. Sputum smears were done
using a Ziehl—Neelsen staining method and sputum cultures
were performed using a broth-based MB/BacT Alert System
(Organon Teknika, Durham, NC, USA). Each subject had
computed tomography (CT) scanning of the chest at baseline
and upon completion of the study. The CT scans were
reviewed by a single, experienced chest radiologist who
was blinded to the patient’s clinical history and to the nature
of the experimental protocol. Symptoms were reviewed
before and after every dose of IFN-g.
All patients provided written informed consent, and the
research protocol was approved by the hospital’s institu-
tional review board (IRB).
PBMC preparation
For a kinetic study of immune responses, 20 ml samples of
peripheral venous bloodwere drawn from subjects prior to the
initiation of IFN-g therapy, at 2, 3, and 6months of treatment,
and2monthsafter the completionof treatment (designatedas
times 0, 2, 3, 6 and 8, respectively in Figures 1—4). Blood
samplesweredrawnonly fromparticipantswhocompleted the
study and not from subjects who discontinued therapy due to
sideeffects. Thenumberof samplesvariedby subject since the
amount of blood taken was not always constant.
PBMCs were isolated from heparinized venous blood by
density gradient centrifugation over Ficoll-PaqueTM PLUS
(Amersham, Upsala, Sweden), and then re-suspended in an
RPMI 1640 medium (Life Technologies, Grand Island, NY, USA)
supplemented with 2 mM of L-glutamine, penicillin G
(100 units/ml), streptomycin (100 mg/ml), and 10% fetal
bovine serum (BioInnovation, Sugarland, TX, USA).
Mycobacterium tuberculosis antigens and
mitogens
To test the proliferative responses of PBMCs, phytohemag-
glutinin (PHA; Sigma Chemical Co., St Louis, MO, USA),
purified protein derivative (PPD; Statens Seruminstitut,
Copenhagen, Denmark), and culture filtrate protein (CFP)
were added at a final concentration of 10 mg/ml to each well
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Figure 1 Proliferative responses of peripheral blood mononuclear cells from multidrug-resistant TB patients during treatment with
IFN-g (PHA, phytohemagglutinin; PPD, purified protein derivative).of a 96-well plate. CFP was prepared by growing M. tuber-
culosis H37Rv in a Sauton medium for about 4 weeks using a
shaking incubator. Bacilli were subsequently removed by
centrifugation. The culture supernatant was then filter-ster-
ilized and concentrated by ultrafiltration using a membrane
cut-off molecular weight of 3 kDa.
Cytokine production and H3-thymidine uptake
proliferation assay
PBMCs (105/well) were stimulated with each antigen or
mitogen for five days in a 96-well microtiter plate. CytokineFigure 3 Time-course of IL-10 responses in peripheral blood
mononuclear cells from multidrug-resistant TB patients treated
with IFN-g (PHA, phytohemagglutinin; CFP, culture filtrate pro-
tein; PPD, purified protein derivative).
Figure 2 Time-course of IFN-g responses in peripheral blood
mononuclear cells from multidrug-resistant TB patients treated
with IFN-g (PHA, phytohemagglutinin; CFP, culture filtrate pro-
tein; PPD, purified protein derivative).production in the supernatant was measured using an ELISA
technique, and the remaining cells were incubated with
1 mCi/well of H3-thymidine (10 Ci/mmol; Amersham, Arling-
ton Heights, IL, USA) for the last 18 hours at 37 8C in a CO2
incubator. The proliferation of lymphocytes was measured by
determination of incorporated H3-thymidine in triplicate
wells using liquid scintillation and a Microbeta counter.
The proliferation was expressed as count per minute
(cpm). The final results were expressed as the stimulation
index (SI), defined as the ratio of cpmwith antigen to the cpm
without antigen (cpm with antigen/cpm without antigen).
Cytokine ELISA assay
Cytokine production in the supernatant of the PBMC culture
was measured using an ELISA technique with pairs of mono-Figure 4 Composition of lymphocyte subsets in peripheral
blood mononuclear cells from multidrug-resistant TB patients
during treatment with IFN-g.
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.clonal antibodies (Becton Dickinson, NJ, USA) for IFN-g and
IL-10. The amount of cytokine production was calculated as
the mean of the triplicate wells after subtraction from the
cytokine level in non-stimulated wells.
Flow cytometry
PBMCs (1  106) were stained with PerCP-, PE-, and FITC-
conjugated monoclonal antibodies to CD3+, CD4+, CD8+,
respectively, and with isotype-matched negative controls
(BD-Pharmingen, San Diego, CA, USA). The labeled samples
(10 000 cells) were analyzed by flow cytometry using a
Coulter Epics Profile II flow cytometer and software (Coulter,
Hialeah, FL, USA).
Statistical analysis
Statistical analysis was performed using version 8.0 of the SAS
program. Mixed procedure was used for longitudinal data
analysis to determine statistically significant differences
among comparison groups. A p value of<0.05 was considered
statistically significant.
Results
Subjects included three men and five women, and clinical
characteristics are summarized in Table 1. No patient was
HIV-seropositive or had a history of insulin-dependent dia-
betesmellitus. All patients had previous histories of receiving
second-line antituberculosis drug chemotherapy for amedian
of 49 months (range 20—101 months). Body weight was
unchanged or decreased slightly in all patients during the
study. No patient had radiographic improvement, as deter-
mined by blinded interpretation of serial chest X-rays and CT
scans by an experienced radiologist. All patients were sputum
smear- and culture-positive at baseline, and none converted
their sputum during the course of IFN-g treatment. Similarly,
the time to positive sputum culture growthwas not prolonged
with IFN-g treatment (from 16.5  6.4 to 11.8  4.9 days).
Most patients tolerated IFN-g treatment. Adverse effects
included headache (six patients), fever (five patients), myal-
gias (three patients), nausea (twopatients), and vomiting (one
patient) (Table 1). Body temperatures typically rose to more
than 39 8C three to five hours after subcutaneous injection of
IFN-g, were sustained for five to seven hours, and then
returned to baseline. Adverse drug effects were classified
according to World Health Organization toxicity criteria.21
Four patients discontinued IFN-g therapy at weeks 15 (two
patients), 19 (one patient), and 21 (one patient) because of
persistent and intolerable adverse reactions such as severe
nausea and vomiting (one subject) and/or intermittent high
fever (three subjects). Although IFN-g and new second-line
antituberculous drug combinations were started concurrently
in all patients, the striking temporal occurrence of side effects
in relation to IFN-g administration, and their quick sponta-
neous resolution suggested they could be attributed to IFN-g.
Monitoring cell-mediated immune responses
T-cell proliferative immune responses to PHA mitogen and
PPD were not significantly enhanced throughout the treat-
ment period compared to pre-treatment responses (Figure 1;
438 S.-K. Park et al.each dot represents the stimulation index obtained from the
PBMCs of one study subject). Proliferative responses after
PHA stimulation were unchanged during IFN-g therapy, and
were significantly decreased at two-months post-treatment
compared to baseline ( p = 0.02). IFN-g production after
stimulation with PHA, CFP, and PPD was not consistently
elevated during the treatment period (although levels did
rise transiently at two months in response to both mycobac-
terial antigens). The levels of IFN-g following mitogen and
PPD stimulation were increased two months after the com-
pletion of therapy compared to pre-treatment levels
(Figure 2), although the increases were not statistically
significant. The production of IL-10 in response to PHA
and M. tuberculosis antigens was reduced throughout
the treatment period (Figure 3), with the IL-10 response
to CFP stimulation significantly reduced at three months of
IFN-g therapy ( p = 0.01). Data points in Figures 2 and 3
represent median patient values of IFN-g and IL-10 produc-
tion, respectively.
Levels of CD8+ T cells in PBMCs increased during the first
two to three months of IFN-g administration, and returned to
baseline levels by two months post-therapy. In contrast,
peripheral blood CD4+ Tcells decreased gradually throughout
the treatment period and did not return to baseline even
after 6months post-treatment (Figure 4). Each dot in Figure 4
represents the percentage of peripheral blood CD4+ or CD8+
T cell populations from one study subject.
Discussion
In our study cohort with chronic and advanced MDR-TB,
subcutaneously administered IFN-g did not result in signifi-
cant improvements in clinical, radiographic, microbiologic,
or immunologic parameters. These results are in contrast to
several small pilot studies involving the use of aerosolized
IFN-g or IFN-a for MDR-TB that have suggested that these
immunomodulating cytokines may be promising adjuvants
capable of enhancing the local immune response to M.
tuberculosis.14—18 One previous pilot study reported the
beneficial effect of systemically administered IFN-g in the
treatment of eight patients with drug-resistant pulmonary
tuberculosis, including MDR-TB, although this benefit was
difficult to assess because of a concurrent change in anti-
tuberculous chemotherapy.19
In an in vitro study with human lung macrophages, IFN-g-
enhanced killing activity of macrophages against M. tuber-
culosis in a dose-dependent manner, administered concur-
rently with a suboptimal dose of 1a,25-dihydroxyvitamin D,
synergistically augmented the effect of IFN-g.22 When admi-
nistered to patients with pulmonary TB, aerosolized IFN-g is
widely distributed and results in significant enhancement of
IFN-g levels in the lower respiratory tract.23 Condos and
colleagues conducted an open-label trial of aerosolized
IFN-g in five patients with sputum smears and cultures per-
sistently positive for MDR-TB.14 Body weight remained stable
or increased, and sputum AFB smears became negative in all
five subjects, and there was an increase in the time to
positive culture (from 17 to 24 days, not significant), suggest-
ing that the mycobacterial burden had decreased. In addi-
tion, the size of cavitary lesions was reduced in all patients at
two months post-treatment. In contrast, in another pilot
study Koh et al. administered aerosolized IFN-g, along withstandard antituberculosis therapy, and found that sputum
smears remained persistently positive in all six MDR-TB
patients throughout the study period.18 However, five
patients had radiographic improvement, including three
patients who showed a decrease in the size of cavitary
lesions. In one patient who demonstrated substantial clinical
and radiologic improvement, pulmonary resection was suc-
cessfully performed. Giosue et al. administered aerosolized
IFN-a as an adjunct to conventional treatment to seven
patients with MDR-TB.16 Five patients became sputum AFB
smear-negative. In another phase II trial of recombinant IFN-
a in patients with advanced and intractable MDR-TB, only
two of five subjects became persistently sputum smear-and
culture-negative after treatment.17
It has been previously reported that patients presenting
with clinically and radiographically less-advanced tubercu-
losis (i.e., smear-negative, non-cavitary) may have a local
immune response characterized by a predominance of lym-
phocytes and locally-secreted IFN-g, suggesting a Th1
response.24 Successful treatment of tuberculosis has been
previously shown to correlate with an increase in Th1 immune
responses (e.g., secretion of IFN-g and IL-12) and a decrease
in Th2 responses (e.g., secretion of IL-10) from PBMCs.25—28
Interestingly, in our cohort at three months post-therapy IL-
10 production in response to M. tuberculosis antigens had
significantly declined nearly to zero, and in parallel with
declining frequencies of CD4+ T cells in PBMCs. Meanwhile,
frequencies of CD8+ T cells were increased at three months
post-therapy and then decreased slightly by the end of
treatment. This observation suggests that IL-10 producing
a regulatory Tcell population (CD4+CD25+) had been induced
before therapy and subsequently declined with exogenous
IFN-g treatment.29 Subsequently, CD8+ T cell population
increased due to the reduction of IL-10, in agreement with
a previous report that IL-10 may modulate the development
of CD8+ T cells.30 Effective antituberculosis chemotherapy
shifts CD4+ cells from affected body fluids to the blood
circulation, accompanied by a change from a Th0 to a Th1
cytokine profile in PBMCs.31
In our study, Th1 immune responses were not induced, and
Th2 responses appeared to be suppressed by subcutaneous
IFN-g treatment. Among PBMCs, there was a gradual
decrease in the CD4+ T cell composition while the level of
CD8+ Tcells was relatively maintained. Active pulmonary TB
is associated with apoptosis (of CD4+ and non-CD4+ cells) and
T-cell hyporesponsiveness, and IFN-g is also known to induce
the apoptosis of CD4+ cells.32 Thus, the combined effect of
IFN-g-induced CD4+ T cell apoptosis and the progression of
the disease may have reduced the composition of CD4+ Tcells
in circulating PBMCs. Further analysis of immune responses
induced by exogenously administered interferon may help to
improve the efficacy of IFN-g immunotherapy in patients with
advanced MDR-TB.
IFN-g treatment was found to increase expression of a few
genes, including an IFN-inducible 10-kDa protein (IP-10) in
BAL cells from TB patients who had been treated with aero-
solized IFN-g in conjunction with standard drug therapy.33 In
this study, however, the gene expression of inducible nitric
oxide synthase (iNOS) was not induced in BAL cells. In addi-
tion, Condos and coworkers found that aerosol administered
IFN-g activated signal transduction pathways and gene
expression in BAL cells from patients with TB.34 Four weeks
Subcutaneous IFN-g for multidrug-resistant TB 439following antituberculous therapy, patient symptoms and
chest radiographs were improved, and all patients showed
increase in the DNA-binding activity of STAT-1, IRF-1, and/or
IRF-9 in BAL cells. Therefore, there is a suggestion that
aerosolized IFN-g may induce the expression of some down-
stream genes and transcription factors that mediate the
protective immune responses to TB, and that the activation
of these IFN-g-mediated immune responses may improve
clinical manifestations.
In all of the aforementioned trials, aerosol administration
of IFN-g was associated with few, if any, adverse systemic
effects. While subcutaneously administered IFN-g was rela-
tively well-tolerated by our patients during the initial stage
of treatment, prolonged use necessitated discontinuation of
IFN-g therapy in one-half of subjects due to high fever or
intractable nausea or vomiting.
In conclusion, aerosolized IFN appears to be useful in the
management of multidrug-resistant pulmonary TB that
responds poorly to available treatment. However, in this
uncontrolled study adjunctive immunotherapy with subcu-
taneously administered IFN-g did not produce significant
clinical, radiographic, microbiologic, or immunologic bene-
fits in patients with MDR-TB. Prospective, controlled clinical
trials comparing locally and systemically administered IFN-g
are needed to define the most effective route of IFN-g
administration for MDR-TB patients.
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